Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone646-975-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.70 million
Profitability
Miscellaneous
Employees64
OptionableOptionable
Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions
What is Progenics Pharmaceuticals' stock symbol?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."
How were Progenics Pharmaceuticals' earnings last quarter?
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings data on Tuesday, July, 31st. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.02. The biotechnology company had revenue of $3.88 million for the quarter, compared to analyst estimates of $3.30 million. Progenics Pharmaceuticals had a negative net margin of 341.78% and a negative return on equity of 66.86%. View Progenics Pharmaceuticals' Earnings History.
When is Progenics Pharmaceuticals' next earnings date?
What price target have analysts set for PGNX?
4 Wall Street analysts have issued 1-year price objectives for Progenics Pharmaceuticals' stock. Their forecasts range from $6.50 to $15.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $11.6250 in the next twelve months. This suggests a possible upside of 137.2% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.
What is the consensus analysts' recommendation for Progenics Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.
Has Progenics Pharmaceuticals been receiving favorable news coverage?
News articles about PGNX stock have trended neutral recently, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Progenics Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Progenics Pharmaceuticals' key competitors?
Some companies that are related to Progenics Pharmaceuticals include Zai Lab (ZLAB), Theravance Biopharma (TBPH), Myovant Sciences (MYOV), Innoviva (INVA), Prestige Consumer Healthcare (PBH), Allakos (ALLK), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), TherapeuticsMD (TXMD), Clovis Oncology (CLVS), Uniqure (QURE), Corcept Therapeutics (CORT), Cambrex (CBM), Spectrum Pharmaceuticals (SPPI) and Phibro Animal Health (PAHC).
Who are Progenics Pharmaceuticals' key executives?
Progenics Pharmaceuticals' management team includes the folowing people:
- Mr. Mark R. Baker, CEO & Director (Age 64)
- Mr. Patrick Fabbio, Sr. VP, CFO & Principal Accounting Officer (Age 51)
- Dr. Vivien Wong, Exec. VP of Devel. (Age 62)
- Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46)
- Melissa Downs, Sr. Mang. of Investor Relations
Who are Progenics Pharmaceuticals' major shareholders?
Progenics Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.00%), Eagle Asset Management Inc. (5.32%), Phocas Financial Corp. (2.01%), Pinnacle Associates Ltd. (1.71%), Royce & Associates LP (1.65%) and Bank of New York Mellon Corp (1.37%). View Institutional Ownership Trends for Progenics Pharmaceuticals.
Which major investors are selling Progenics Pharmaceuticals stock?
PGNX stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Hikari Power Ltd, Pinnacle Associates Ltd., Bank of America Corp DE, Royce & Associates LP, Phocas Financial Corp., MetLife Investment Advisors LLC and Northern Trust Corp. View Insider Buying and Selling for Progenics Pharmaceuticals.
Which major investors are buying Progenics Pharmaceuticals stock?
PGNX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, BlackRock Inc., Squarepoint Ops LLC, Oregon Public Employees Retirement Fund, Geode Capital Management LLC, Worth Venture Partners LLC and Fosun International Ltd. View Insider Buying and Selling for Progenics Pharmaceuticals.
How do I buy shares of Progenics Pharmaceuticals?
Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Progenics Pharmaceuticals' stock price today?
One share of PGNX stock can currently be purchased for approximately $4.90.
How big of a company is Progenics Pharmaceuticals?
Progenics Pharmaceuticals has a market capitalization of $414.26 million and generates $11.70 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Progenics Pharmaceuticals employs 64 workers across the globe.
What is Progenics Pharmaceuticals' official website?
How can I contact Progenics Pharmaceuticals?
Progenics Pharmaceuticals' mailing address is 285 FULTON STREET 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]
MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
